HUDDINGE, Sweden, April 1, 2020 /PRNewswire/ -- Today, on 1 April 2020, Karo Pharma is publishing its annual report for 2019 on the company's website, www.karopharma.com.
ABOUT KARO PHARMA
Karo Pharma specialises in the sales and marketing of prescription drugs and over the counter products for everyday healthcare. Karo Pharma is headquartered in Stockholm, Sweden, and quoted on Nasdaq Stockholm Mid Cap.
This information is information that Karo Pharma is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on 1 April, at 15:00 CET.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Jon Johnsson, CFO +46-735-078-861 [email protected]
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...
Bruker Corporation today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current...
Gilead Sciences, Inc. announced today its first quarter 2024 results of operations.
"Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and...
DexCom, Inc. today reported its financial results as of and for the quarter ended March 31, 2024.
First Quarter 2024 Financial Highlights:
Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an...
